Research Topics
| Jan OldenburgSummaryAffiliation: The Norwegian Radium Hospital Country: Norway Publications
| Collaborators
|
Detail Information
Publications
Genetic variants associated with cisplatin-induced ototoxicityJan Oldenburg
Department of Clinical Cancer Research, The Norwegian Radium Hospital, Rikshospitalet, Montebello, 0310 Oslo, Norway
Pharmacogenomics 9:1521-30. 2008..This review will address the prevalence of cisplatin-induced ototoxicity, its pathophysiology, quantification and associations with genetic variants. The recent progress in both phenotyping and genotyping is discussed...- Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivorsJan Oldenburg
Department of Clinical Cancer Research, Rikshospitalet Radiumhospitalet Medical Center, Montebello, Oslo, Norway
J Clin Oncol 25:708-14. 2007..These differences might be a result of functional polymorphisms in cisplatin-detoxifying enzymes like glutathione S-transferases (GSTs)... - Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional studyJan Oldenburg
Department of Clinical Cancer Research, The Norwegian Radiumhospital, Oslo, Norway
J Transl Med 5:70. 2007..To assess the impact of polymorphisms in Glutathione S-transferase (GST) -P1, -M1, and -T1 on self-reported chemotherapy-induced long-term toxicities in testicular cancer survivors (TCSs)... - Functional glutathione S-transferase genotypes among testicular germ cell tumor survivors: associations with primary and post-chemotherapy tumor histologySigrid M Kraggerud
Department of Cancer Prevention, Centre for Cancer Biomedicine, The Norwegian Radium Hospital, Drammen, Norway
Pharmacogenet Genomics 19:751-9. 2009.... - Late relapse of nonseminomatous germ cell tumoursJan Oldenburg
The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
BJU Int 104:1413-7. 2009..Referral of late-relapsing patients to high-volume institutions ensures the best chances of cure and enables increasing understanding of tumour biology and the clinical course of these patients... - Fear of recurrence in long-term testicular cancer survivorsTone Skaali
Department of Clinical Cancer Research, The Norwegian Radiumhospital, Rikshospitalet University Hospital, Oslo, Norway
Psychooncology 18:580-8. 2009..To explore fear of recurrence (FoR) in long-term testicular cancer survivors (TCSs) since FoR hardly has been examined in TCSs... - Short- and long-term morbidity after treatment for testicular cancerSophie D Fossa
The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
BJU Int 104:1418-22. 2009..Patients should be informed about these potential complications and the importance of adjusting their lifestyle (e.g. smoking habits, physical activity and weight control)... - Late relapse of germ cell tumorsJan Oldenburg
Department of Oncology, The Norwegian Radium Hospital, Oslo, Norway
Hematol Oncol Clin North Am 25:615-26, x. 2011..Salvage chemotherapy should be based on a representative biopsy. Referring patients with late relapse to high-volume institutions ensures the best chances of cure and enables multimodal treatment... - Late relapse of germ cell tumorsJan Oldenburg
Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway
World J Urol 27:493-500. 2009..To assess the main characteristics of late relapsing malignant germ cell tumors (MGCTs). These tumors are rare and occur by definition 2 years or later after successful treatment... - [Testicular cancer]Jan Oldenburg
Fagområde Klinisk kreftforskning, Kreftklinikken Radiumhospitalet, Rikshospitalet, 0310 Oslo
Tidsskr Nor Laegeforen 128:457-60. 2008..Testicular cancer is the most common type of cancer among Norwegian 15 to 40-year-old men. The incidence has doubled in Norway and Denmark during the last 50 years and is currently the highest in the world... - Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor massesJan Oldenburg
Department of Medical Oncology, The Norwegian Radium Hospital, Montebello, Oslo, Norway
J Clin Oncol 21:3310-7. 2003..Therefore, postchemotherapy RPLND remains necessary in patients with minimal-size residual lesions to facilitate easy and safe follow-up and initiate additional therapy as early as possible, thus avoiding recurrences... - Late relapses of germ cell malignancies: incidence, management, and prognosisJan Oldenburg
Department of Clinical Cancer Research, University of Oslo, Rikshospitalet Radiumhospitalet Medical Center, Oslo, Norway
J Clin Oncol 24:5503-11. 2006..Referral of late-relapsing patients to high-volume institutions ensures the best chances of cure and enables increasing understanding of tumor biology and the clinical course of these patients... - Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivorsJan Oldenburg
Faculty of Medicine, University of Oslo, 0310, Oslo, Norway
Qual Life Res 15:791-800. 2006..CONCLUSION: The SCIN shows good psychometric properties, and is recommended as a brief screening instrument for chemotheraphy-indeed neurotoxicity... - Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancerMette Sprauten
Department of Clinical Cancer Research, Norwegian Radium Hospital, Postboks 4953 Nydalen, N 0424 Oslo, Norway
J Clin Oncol 30:300-7. 2012..CONCLUSION Here we document a significant relationship between increasing levels of residual serum platinum and NTX severity after adjusting for initial cisplatin dose...